Medpace Faces Securities Fraud Allegations, Stock Drops 16%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MEDP?
Source: PRnewswire
- Securities Fraud Allegations: Medpace Holdings Inc. is facing securities fraud allegations for allegedly understating cancellation rates and overstating its book-to-bill ratio, resulting in a significant 16% drop in stock price, which severely impacts investor confidence.
- Stock Price Decline: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05 per share, indicating serious concerns about the company's financial health.
- Legal Action Developments: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace and its executives, with investors urged to apply to lead the case by June 8, 2026, highlighting the potential for escalating legal risks that could further strain the company's finances.
- Executive Departure Impact: The resignation of President Jesse Geiger has added to the uncertainty surrounding Medpace's future, leading to an additional 23% decline in stock price during afternoon trading on April 23, 2026, reflecting market apprehension about leadership stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 417.540
Low
462.00
Averages
569.17
High
660.00
Current: 417.540
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Stock Target Cut Following Earnings Report Miss
- Earnings Report Impact: Medpace Holdings Inc. reported a fourth-quarter book-to-bill ratio of 1.04x on February 9, 2026, significantly below the management's guidance of 1.15x, resulting in a stock price drop of $84.30, or over 15.9%, closing at $446.05, reflecting a pessimistic market outlook on the company's future.
- Analyst Downgrades: Truist lowered its price target for Medpace from $555 to $539 while maintaining a Hold rating, noting that 76% of the quarterly growth came from indirect revenue, indicating a deteriorating business environment in key therapeutic areas and diminishing analyst confidence in future growth.
- Increased Legal Risks: A securities class action has been filed against Medpace, alleging that the company misled investors between April 22, 2025, and February 9, 2026, by failing to disclose elevated cancellation rates, potentially exposing investors to significant losses.
- Market Reaction and Investor Confidence: The analyst reactions to Medpace's earnings miss highlight the market's over-reliance on management's prior guidance, and when such guidance is revealed to be misleading, it severely undermines investor confidence, potentially leading to broader market volatility.
See More
Medpace Faces Securities Fraud Allegations, Stock Drops 16%
- Securities Fraud Allegations: Medpace Holdings Inc. is facing securities fraud allegations for allegedly understating cancellation rates and overstating its book-to-bill ratio, resulting in a significant 16% drop in stock price, which severely impacts investor confidence.
- Stock Price Decline: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05 per share, indicating serious concerns about the company's financial health.
- Legal Action Developments: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace and its executives, with investors urged to apply to lead the case by June 8, 2026, highlighting the potential for escalating legal risks that could further strain the company's finances.
- Executive Departure Impact: The resignation of President Jesse Geiger has added to the uncertainty surrounding Medpace's future, leading to an additional 23% decline in stock price during afternoon trading on April 23, 2026, reflecting market apprehension about leadership stability.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc., involving investors who purchased shares between April 22, 2025, and February 9, 2026, alleging the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became apparent through poor performance throughout the class period, resulting in significant damages for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- Legal Process: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, indicating the urgency of the case and reflecting investor concerns regarding corporate governance and transparency.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in investor protection matters.
See More
Medpace Holdings Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements regarding Medpace's backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and resources in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success records to ensure effective legal representation in class actions, avoiding firms that merely act as intermediaries without actual litigation experience.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline to contact the firm by June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which resulted in investor losses once the truth was revealed, highlighting the company's misconduct in the market.
- Loss Recovery Opportunity: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free legal consultations to help investors protect their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
Medpace Stock Target Cut Following Earnings Report Miss
- Earnings Report Impact: Medpace Holdings Inc. reported a fourth-quarter book-to-bill ratio of 1.04x on February 9, 2026, significantly below the management's guidance of 1.15x, resulting in a stock price drop of $84.30, or over 15.9%, closing at $446.05, reflecting a pessimistic market outlook on the company's future.
- Analyst Downgrades: Truist lowered its price target for Medpace from $555 to $539 while maintaining a Hold rating, noting that 76% of the quarterly growth came from indirect revenue, indicating a deteriorating business environment in key therapeutic areas and diminishing analyst confidence in future growth.
- Increased Legal Risks: A securities class action has been filed against Medpace, alleging that the company misled investors between April 22, 2025, and February 9, 2026, by failing to disclose elevated cancellation rates, potentially exposing investors to significant losses.
- Market Reaction and Investor Confidence: The analyst reactions to Medpace's earnings miss highlight the market's over-reliance on management's prior guidance, and when such guidance is revealed to be misleading, it severely undermines investor confidence, potentially leading to broader market volatility.
See More
Medpace Faces Securities Fraud Allegations, Stock Drops 16%
- Securities Fraud Allegations: Medpace Holdings Inc. is facing securities fraud allegations for allegedly understating cancellation rates and overstating its book-to-bill ratio, resulting in a significant 16% drop in stock price, which severely impacts investor confidence.
- Stock Price Decline: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05 per share, indicating serious concerns about the company's financial health.
- Legal Action Developments: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Medpace and its executives, with investors urged to apply to lead the case by June 8, 2026, highlighting the potential for escalating legal risks that could further strain the company's finances.
- Executive Departure Impact: The resignation of President Jesse Geiger has added to the uncertainty surrounding Medpace's future, leading to an additional 23% decline in stock price during afternoon trading on April 23, 2026, reflecting market apprehension about leadership stability.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc., involving investors who purchased shares between April 22, 2025, and February 9, 2026, alleging the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became apparent through poor performance throughout the class period, resulting in significant damages for investors once the truth was revealed, highlighting serious deficiencies in the company's disclosure practices.
- Legal Process: Investors must apply by June 5, 2026, to be appointed as lead plaintiffs, indicating the urgency of the case and reflecting investor concerns regarding corporate governance and transparency.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in investor protection matters.
See More
Medpace Holdings Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that defendants made false and/or misleading statements regarding Medpace's backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and resources in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success records to ensure effective legal representation in class actions, avoiding firms that merely act as intermediaries without actual litigation experience.
See More
Investor Class Action Lawsuit Reminder
- Gossamer Bio Lawsuit: Gossamer Bio (NASDAQ:GOSS) faces a class action lawsuit for failing to disclose the true conditions of Latin American patients, resulting in its Phase 3 PROSERA study not meeting primary endpoints, with a lead plaintiff deadline of June 1, 2026.
- New Era Energy Issues: New Era Energy & Digital (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent activities, with investors needing to file by June 1, 2026, facing risks of misleading financial results.
- Medpace Holdings Allegations: Medpace Holdings (NASDAQ:MEDP) is accused of overselling its projected book-to-bill ratio for Q4 2025, with a lead plaintiff deadline of June 5, 2026, potentially indicating a weak business environment.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses in these companies to contact their firm to understand their legal rights and ensure protection in the class actions.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws during the period from April 22, 2025, to February 9, 2026, with a deadline to contact the firm by June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its share price, which resulted in investor losses once the truth was revealed, highlighting the company's misconduct in the market.
- Loss Recovery Opportunity: Affected shareholders are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free legal consultations to help investors protect their rights.
- Lawsuit Status Explanation: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially affecting their rights to claim damages.
See More
